• Advances in the Understanding of Etiology (I)
• 30 min
  1. Infection and autoimmunity: a two-way relationship

  • Dr. Ricard Cervera
• 35 min
  2. Autoimmunity and atherosclerosis

  • Prof. Johan Frostegard
• 47 min
  3. Endothelium and autoimmunity

  • Prof. Pier Luigi Meroni
• Advances in the Understanding of Etiology (II)
• 22 min
  4. Prolactin has a pathogenic role in systemic lupus erythematosus

  • Prof. Luis Jara-Quezada
• 44 min
  5. Sjögren's syndrome: current knowledge and future prospects

  • Prof. Athanasios G. Tzioufas
• 51 min
  6. Genetic and environmental triggers of autoimmune thyroid diseases

  • Prof. Yaron Tomer
• Advances in Pathogenesis and Clinical Manifestation
• 38 min
  7. The catastrophic antiphospholipid syndrome and the microangiopathic antiphospholipid syndrome

  • Prof. Ronald Asherson
• 20 min
  8. Pathogenic mechanisms of autoantibodies: circulating and local antibodies that form immune complexes

  • Dr. Luís Eduardo Coelho Andrade
• 34 min
  9. Pathogenic mechanisms of autoantibodies: antibodies to intracellular and membrane-bound antigens

  • Dr. Luís Eduardo Coelho Andrade
• 43 min
  10. What causes primary biliary cholangitis?

  • Dr. M. Eric Gershwin
• 30 min
  11. Capillaroscopy in autoimmune rheumatic diseases

  • Prof. Maurizio Cutolo
• Advances in Diagnostic Methodologies (I)
• 26 min
  12. The past, present & future of ANA testing: history and challenges of ANA

  • Prof. Marvin J. Fritzler
• 33 min
  13. The past, present & future of ANA testing: changing bandwidth and future of ANA

  • Prof. Marvin J. Fritzler
• 36 min
  14. Diagnostic methods in autoimmunity

  • Mr. Steven Binder
• 24 min
  15. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 1

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 28 min
  16. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 2

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 48 min
  17. Novel aspects of systemic sclerosis

  • Prof. Gabriele Valentini
• Advances in Diagnostic Methodologies (II)
• 46 min
  18. An update on the multiple faces of celiac disease

  • Prof. Aaron Lerner
• 23 min
  19. Protective autoantibodies

  • Prof. Elias Toubi
• 32 min
  20. CD44 genetic deletion enhances and CD44 antibody targeting attenuates autoimmune inflammation

  • Prof. David Naor
• 44 min
  21. Rheumatic fever: a model of a post-infectious autoimmune disease

  • Prof. Jorge Kalil
• Treatments of autoimmune diseases
• 38 min
  22. Intravenous immunoglobulins: clinical evidence

  • Prof. Shaye Kivity
• Latest Developments in the Field
• 26 min
  23. Adjuvants and autoimmunity

  • Dr. Eitan Israeli
• 46 min
  24. Antiphospholipid syndrome (APS): from pathogenesis to treatment

  • Prof. Roger Levy
• 24 min
  25. Vitamin D and autoimmunity

  • Dr. Shir Azrielant
• 28 min
  26. Pregnancy in rheumatic diseases

  • Prof. Pier Luigi Meroni
• Archived Lectures *These may not cover the latest advances in the field
• 47 min
  27. Pathogenic mechanisms of autoantibodies

  • Prof. Cees Kallenberg
• 41 min
  28. B lymphocytes on the frontline of autoimmunity

  • Prof. Pierre Youinou
• 42 min
  29. Apoptotic cell clearance deficiency

  • Prof. Martin Herrmann
• 34 min
  30. Auto-antibodies as predictors of autoimmune disease

  • Dr. Nicola Bizzaro
• 46 min
  31. Innate immunity and natural autoantibodies

  • Prof. Luc Mouthon
• 45 min
  32. Accelerated atherosclerosis in autoimmune rheumatic disease

  • Dr. Andrea Doria
• 47 min
  33. Pregnancy in autoimmune rheumatic diseases

  • Prof. Angela Tincani
• 42 min
  34. Pulmonary hypertension in the connective tissue disease pathogenesis, clinical features and therapeutic options in 2006

  • Prof. Ronald Asherson
• 39 min
  35. Use of algorithms for high quality diagnostics and handling of patients with autoimmune rheumatic diseases

  • Dr. Allan Wiik
• 24 min
  36. Immunologic mechanisms in systemic lupus erythematosus

  • Prof. Kok-Yong Fong
• 23 min
  37. Osteoimmunology

  • Prof. João Eurico Fonseca
  • Ms. Joana Caetano-Lopes
• 43 min
  38. ANCA-associated systemic vasculitides

  • Prof. Loic Guillevin
• 23 min
  39. The common origin for diverse autoimmune diseases

  • Prof. Juan-Manuel Anaya
• 76 min
  40. Anti-cytokine therapy in rheumatoid arthritis

  • Prof. Piercarlo Sarzi-Puttini
• 40 min
  41. Sjogren's syndrome: autoimmune epithelitis

  • Prof. Haralampos Moutsopoulos
• 31 min
  42. Vitamin D and autoimmunity

  • Dr. Howard Amital
• 25 min
  43. Intravenous immunoglobulins: myth and reality

  • Prof. Zera Tellier

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Dramatic new developments in past few years
3. Pulmonary hypertension response
4. Pulmonary hypertension (PHT)
5. Epidemiology and pathophysiology
6. Diagnostic and treatment challenges
7. WHO classification of pulmonary hypertension
8. New York Heart Association classification
9. WHO organization functional classification 1973
10. Main difference between the two classifications
11. Pathogenesis of pulmonary hypertension
12. Imbalance of vascular effectors
13. Roles of vascular effectors
14. Production of fibromuscular changes
15. PHT genetic and immunological factors
16. PHT characteristics: summary
17. The various factors involved in PHT pathogenesis
18. Role of anti-phospholipid antibodies in PHT
19. Clue for anti-phospholipid antibodies role in PHT
20. Pulmonary hypertension and systemic sclerosis
21. PHT and anti-phospholipid antibodies: conclusions
22. Role of T cells in PHT pathogenesis
23. Conditions with CD4 cell defects and PAH
24. Depletion of CD4 cells and autoimmune disease
25. Autoimmune aspects of PHT
26. PHT may precede the connective tissue disease
27. Some idiopathic HPT patients are ANF positive
28. Anticentromere antibody
29. Pulmonary arterial hypertension (PAH) and HIV
30. Relationship to AIRE gene
31. APECED is a condition of AIRE loss of function
32. PAH reported following splenectomy
33. Clinical manifestations
34. Signs of pulmonary hypertensions
35. Regular routine examinations and PHT signs
36. X-ray finding of PHT
37. Electrocardiography might alert of PAH presence
38. Laboratory tests
39. Predisposing factors in thromboembolic PAH (1)
40. Predisposing factors in thromboembolic PAH (2)
41. Diagnosis and severity assessment of PAH
42. Chronic thromboembolic pulmonary hypertension
43. Embolism travels up to heart and lungs
44. Histology seen in the lungs
45. Histological lesions
46. Examples of vascular pathology
47. Intimal proliferation in pulmonary hypertension
48. Medial hypertrophy of the pulmonary arterial
49. Pulmonary artery lumen and lymphocyte infiltration
50. Poor prognostic factors
51. Causes of death
52. Prognosis of PAH
53. Survival of pulmonary hypertension patients
54. PHT in connective tissue disorders
55. Form of PHT in connective tissue disorders
56. PHT type variation in connective tissue diseases
57. PAH in the different connective tissue disorders
58. Pulmonary hypertension in SLE
59. Types of pulmonary hypertension in SLE
60. PHT in SLE and it's associations
61. PHT and systemic sclerosis characteristics
62. Frequency of PAH and fibrosis in SSc patients
63. PAH from heart involvement
64. Echocardiogram and diastolic dysfunction
65. Onset of PAH is often delayed
66. Screening of patients with SSc for PAH
67. Use of DLCO
68. DLCO in patients who developed PAH vs. controls
69. The ratio FVC% / DLCO% is very helpful
70. FVC/DLCO ratio between 1.6 - 1.8
71. Cardiopulmonary findings in limited SSc with PAH
72. Autoantibodies in PAH cases and controls
73. Frequency of auto-antibodies in all SSc patients
74. Echocardiography
75. Echo may indicate PAH but does not diagnose it
76. Risk factors for PAH in systemic sclerosis
77. Making diagnosis of PAH
78. Right heart catheterization as PAH measurement
79. Dyspnoea/significant mortality and PAH in SSc
80. Natural history of elevated PASP in SSc
81. Incidence of HLA DRw52 gene/DR3/DR6 antigens
82. Anti-phospholipid antibodies
83. Rheumatoid arthritis and PHT
84. Elevations of pulmonary arterial pressures
85. Sjogren's syndrome and PHT
86. Treatment
87. Improved survival for patients with IPAH
88. Approved therapy for SSc PHT
89. Treprostinal or inhaled iloprost treatment
90. Continuous i.v. therapy for SSc PHT
91. Other therapies for SSc PHT
92. Comments on PAH therapy
93. New compounds being currently tested
94. Supportive therapy
95. Treatment is dependent on type of lung disease
96. PHT in diffuse SSc
97. Summary of PAH in SSc
98. Acknowledgments

Topics Covered

• Diagnosis of pulmonary arterial hypertension (PAH)
• Classification of the types of PAH
• Pathogenesis
• Role of endothelin 1
• Role of prostacyclin/thromboxane
• Role of antiphospholipid antibodies
• CD4 cells and PAH in HIV infection and autoimmune diseases
• PAH in SLE, systemic sclerosis and CREST syndrome
• Rheumatoid arthritis, Sjogren's syndrome
• Autoimmune aspects of "primary" idiopathic PAH
• Clinical manifestations of PAH
• Thromboembolic PAH
• New therapies with endothelin 1 antagonists (non-selective and selective), prostacyclin analogues (inhaled and IV) and phosphodiesterase inhibitors (e.g. sildenafil)

Links

Series:

• Autoimmunity

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Asherson, R. (2007, October 1). Pulmonary hypertension in the connective tissue disease pathogenesis, clinical features and therapeutic options in 2006 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/ULWT7738.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Prof. Ronald Asherson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.